The results of a Canadian study showed that there were no differences in BMD,
turnover, or bone strength indexes in people who used PPI for long periods of time relative to nonusers of PPI.
Past studies suggest that there is a very weak correlation between hip fractures and
proton-pump inhibitors (PPI). There is still no significant evidence of the causality
or mechanism of the effects behind this association. A study in Manitoba, Canada examined the
changes in bone strength and structure in 52 in PPI users with over 5 years of PPI use
compared to 52 nonusers; the mean overall age of both sample groups was 65.
The results of the study showed that the cortical bone mineral mass between the two sample groups were similar. The investigations showed that age was the only risk factor for changes in bone mineral mass. Ultimately, the researchers found that long-term PPI use does not make
patients more vulnerable to bone fractures, and does not seem to alter bone structure
and bone strength.